Dr James McIlroy MBChB BMedSci (Hons)
Entrepreneur | Medical Doctor | Speaker
Developing and advancing bio-pharmaceutical innovations to sustain and improve human health.
I Founded EnteroBiotix after recognising the therapeutic potential of the microbiome with the vision of building one of world’s leading microbiome drug development companies. I have over 5 years of leadership experience as a biopharmaceutical entrepreneur, Board Director and company executive, with hands on experience in creating, building and successfully leading cross-functional teams within fast growing companies that have gone on to deliver significant value building milestones for shareholders.
Having successfully raised multiple rounds of equity investment from private and corporate syndicates with deal values in aggregate value of >£10m, I also secured multiple large grant funding awards from high-profile funding bodies such as the Medical Research Council and Innovate UK.
I am a qualified medical doctor who has successfully completed training posts within the UK National Health Service in multiple hospital service areas including: Acute Internal Medicine, General Surgery and Medical Paediatrics. I hold a BMedSci (Hons) from the University of Edinburgh and an MBChB from the University of Aberdeen, graduating with a final year distinction (top 3% of year) and the elective prize in child health awarded in recognition of my published research on intestinal microbiome modulation in paediatric patient populations.
I was the first undergraduate to be awarded an Enterprise Fellowship by the Royal Society of Edinburgh and is the youngest recipient of a Visiting Research Fellowship by United European Gastroenterology. I am currently appointed as Honorary Lecturer in Healthcare Innovation at the University of Aberdeen, Advisory Board member at Innovate UK/KTN Microbiome Special Interest Group and am Co-Founder of the Intestinal Microbiome-based Medicines European Task Group (IMM-ETG).
I am a named inventor on several microbiome related patent applications and have been published as first author in journals such as Alimentary Pharmacology & Therapeutics, Frontline Gastroenterology and Clinical Immunology.